Herantis Pharma Plc’s Board decision on new stock option program for key employees
Herantis Pharma Plc
Company release 31 Aug 2018 at 9:00 AM
The Board of Directors of Herantis Pharma Plc (“Herantis”) has decided on a new stock option program 2018 I, according to which stock options are offered to key employees of the company. There is a weighty financial reason to issue the options as they will be offered to key employees to increase their commitment toward long-term contribution to growing shareholder value in Herantis.
The maximum total number of option rights issued shall be 100,000. Each option entitles to subscribing for one ordinary share of Herantis Pharma Plc for a subscription price of €5.85 per share. The options will be offered without consideration.
The stock options to be given based on the new stock option program correspond to approximately 2.0% of all shares and votes in Herantis after all possible share subscriptions. The new stock option program is based on the authorization by the Annual General Meeting of Herantis on the 9th of April 2015.
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.